Clinical Trials Using Irinotecan Hydrochloride

Clinical trials are research studies that involve people. The clinical trials on this list are studying Irinotecan Hydrochloride. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-36 of 36

  • Combination Chemotherapy and Binimetinib in Treating Patients with RAS Positive Metastatic Colorectal Cancer

    This phase Ib trial studies the side effects and best doses of combination chemotherapy when given together with binimetinib in patients with RAS positive colorectal cancer that has spread from the primary site (place where it started) to other places in the body (metastatic). Drugs used in chemotherapy, such as fluorouracil and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Binimetinib works in different ways to stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with binimetinib may kill more tumor cells.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of gFOLFIRINOX in Treating Patients with Locally Advanced Gastroesophageal or Stomach Cancer

    This pilot phase I trial studies genetic analysis-guided irinotecan hydrochloride dosing of genotype-directed fluorouracil, irinotecan hydrochloride, leucovorin, oxaliplatin (gFOLFIRINOX) with or without trastuzumab in treating patients with gastroesophageal or stomach cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced). Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin may also help fluorouracil work better. Trastuzumab binds to human epidermal growth factor 2 (HER2) on the surface of HER2-positive cancer cells, and may kill tumor cells. Genetic analysis may help doctors determine what dose of irinotecan hydrochloride patients can tolerate.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Combination Chemotherapy before and after Surgery in Treating Patients with Pancreatic Cancer That Can Be Removed by Surgery

    This phase II trial studies how well combination chemotherapy before and after surgery works in treating patients with pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery.
    Location: Yale University, New Haven, Connecticut

  • Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

    The purpose of this study is to determine a well-tolerated dose of Carfilzomib in combination with Irinotecan (Phase 1b portion of the study) in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers and to assess the 6 month survival of relapsed small cell lung cancer patients treated with this combination therapy. **The Phase 1b portion of the study is now complete**. Phase 2 portion of the study. The safest, maximally tolerated dose established as established in Phase 1 for Phase 2 is as follows -- Carfilzomib will be provided at 20 / 36 mg / m2 with Irinotecan dosed at 125 mg / m2. The purpose of the Phase 2 portion of the study is to assess 6 month survival of relapsed small cell lung cancer ins subjects treated with this combination therapy.
    Location: See Clinical Trials.gov

  • Venetoclax and Irinotecan for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

    This phase I / II trial investigates the best dose of venetoclax when given together with irinotecan and to see how well they work in treating patients with small cell lung cancer that has come back (relapsed) or does not respond to treatment (refractory). Chemotherapy drugs, such as venetoclax, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving venetoclax together with irinotecan may kill more tumor cells in patients with small cell lung cancer.
    Location: Virginia Commonwealth University / Massey Cancer Center, Richmond, Virginia

  • Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy with FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

    This phase I trial investigates the best dose, possible benefits and / or side effects of BAY 1895344 in combination with FOLFIRI in treating patients with stomach or intestinal cancer that is unlikely to be cured or controlled with treatment or has spread to other places in the body (advanced or metastatic). BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as irinotecan, fluorouracil, and leucovorin, (called FOLFIRI in short) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BAY 1895344 in combination with FOLFIRI may help shrink advanced or metastatic stomach and / or intestinal cancer.
    Location: Location information is not yet available.

  • NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine / Nab-Paclitaxel before Surgery for the Treatment of Resectable or Borderline Resectable Pancreatic Cancer

    This phase II trial evaluates whether early switching from modified fluorouracil / irinotecan / leucovorin / oxaliplatin (mFOLFIRINOX) chemotherapy regimen to a combination of gemcitabine and nab-paclitaxel (GA) before surgery is effective in treating patients with pancreatic cancer that can be surgically removed (resectable or borderline resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, oxaliplatin, gemcitabine, and nab-paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The study will also evaluate the drug losartan in combination with mFOLFIRINOX or GA.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • Modified FOLFIRINOX and Stereotactic Body Radiation Therapy for the Treatment of Patients with Non-Metastatic Unresectable Pancreatic Cancer

    This phase II trial studies how well the combination of chemotherapy drugs called FOLFIRINOX (levoleucovorin or leucovorin, 5-fluorouracil, irinotecan and oxaliplatin) followed by stereotactic body radiation therapy works in treating patients with pancreatic cancer that has not spread to other places in the body (non-metastatic) and cannot be removed by surgery (unresectable). Chemotherapy drugs, such as levoleucovorin or leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Stereotactic body radiation therapy is a radiation therapy approach which delivers high dose radiation to a tumor in the body in a single treatment session or up to 5 treatment sessions (one dose per day). Giving chemotherapy with stereotactic body radiation therapy may kill more tumor cells.
    Location: Yale University, New Haven, Connecticut

  • Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients with Metastatic Colorectal Cancer

    This phase I trial studies the best dose and side effects of irinotecan hydrochloride when given with utomilumab and cetuximab in treating patients with colorectal cancer that has spread to other places in the body (metastatic). Monoclonal antibodies, such as utomilumab and cetuximab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving utomilumab, cetuximab, and irinotecan hydrochloride may work better in treating patients with colorectal cancer.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients with Recurrent High-Grade Gliomas

    This phase I trial studies the side effects and best dose of carboxylesterase-expressing allogeneic neural stem cells when given together with irinotecan hydrochloride in treating patients with high-grade gliomas that have come back. Placing genetically modified neural stem cells into brain tumor cells may make the tumor more sensitive to irinotecan hydrochloride. Irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving carboxylesterase-expressing allogeneic neural stem cells and irinotecan hydrochloride may be a better treatment for high-grade gliomas.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Implantable Microdevice for the Evaluation of Drug Response in Patients with Primary Brain Tumors

    This early phase I trial studies the feasibility and safety of an implantable microdevice for the evaluation of drug response in patients with primary brain tumors. Brain tumors are known to be very different from each other and respond differently to different drugs. It would be very helpful to find out what drugs have the best chance of working in each specific tumor. This research study involves drugs that are released by a small device, as small as the tip of a needle, that is inserted by a neurosurgeon into the tumor at the time of surgery and is then removed by the end of the surgery. The goal of this research study is to prove that these small devices can be used to find out which drugs have better effects on treating tumors.
    Location: 2 locations